Phesgo is named as an intervention in 15 current clinical trials in our USA, Spain, Germany, Italy, France, Poland, Brazil, South Korea, UK, Belgium, Mexico, Australia, India, China, Turkey, Taiwan, Canada, Japan, Israel, Sweden, Czechia, Portugal, Egypt, Singapore, Switzerland, Austria, Norway and Denmark registers. 8 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Hoffmann-La Roche (3). The most-studied condition is HER2-positive Breast Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Phesgo. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02)
2025-522431-34-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Region Hovedstaden | Denmark |
| Condition (as registered) | Trials |
|---|---|
| HER2-positive Breast Cancer | 3 |
| HIV Infections | 3 |
| Melanoma | 2 |
| Locally Advanced or Metastatic Breast Cancer | 1 |
| Metastatic Breast Cancer | 1 |
| Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | 1 |
| Early-stage Breast Cancer | 1 |
| Metastatic Breast Cancer With a Isolated Brain Progression | 1 |
| Breast Cancer | 1 |
| Endometrial Carcinoma | 1 |
| Endometrial Clear Cell Adenocarcinoma | 1 |
| Endometrial Dedifferentiated Carcinoma | 1 |
| Endometrial Endometrioid Adenocarcinoma | 1 |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
15 current trials in our USA, Spain, Germany, Italy, France, Poland, Brazil, South Korea, UK, Belgium, Mexico, Australia, India, China, Turkey, Taiwan, Canada, Japan, Israel, Sweden, Czechia, Portugal, Egypt, Singapore, Switzerland, Austria, Norway and Denmark registers name Phesgo (also registered as RHuPH20) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 15 trials are recruiting: 5 with sites in USA, 4 with sites in Spain, 4 with sites in Germany, 3 with sites in Italy, 1 with sites in France, 3 with sites in Poland, 1 with sites in Brazil, 3 with sites in South Korea, 1 with sites in UK, 1 with sites in Belgium, 2 with sites in Mexico, 2 with sites in Australia, 1 with sites in India, 1 with sites in China, 1 with sites in Turkey, 1 with sites in Taiwan, 1 with sites in Canada, 2 with sites in Japan, 1 with sites in Israel, 1 with sites in Sweden, 1 with sites in Czechia, 1 with sites in Singapore and 1 with sites in Denmark. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Hoffmann-La Roche (3), ViiV Healthcare (3), Bristol-Myers Squibb (2) and MedSIR (1), among 10 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Phesgo works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Phesgo works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Phesgo (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.